Wonder why EUA (Europe) seems more cautious in their guidelines for radiotherapy for localised PCa than seen here and in the articles by Allen. Are we too cautious in Europe?
EUA Guidelines said...
Taking into account the published results and the uncertainties of the correct α/β ratio, moderate HFX plus dose escalation should be done by experienced teams, accompanied by meticulous RT quality assessment and close attention to organ at risk dose-constraints until long-term data are available. For extreme HFX, it seems prudent to restrict this therapy to prospective clinical trials and to inform patients on the uncertainties of the long-term outcome.
HFX = Hypofractionation, extreme HFX = SBRT